JP2004527494A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004527494A5 JP2004527494A5 JP2002567337A JP2002567337A JP2004527494A5 JP 2004527494 A5 JP2004527494 A5 JP 2004527494A5 JP 2002567337 A JP2002567337 A JP 2002567337A JP 2002567337 A JP2002567337 A JP 2002567337A JP 2004527494 A5 JP2004527494 A5 JP 2004527494A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament
- endostatin
- retinal
- choroidal
- microcapsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 15
- 239000003094 microcapsule Substances 0.000 claims 11
- 102100016705 COL18A1 Human genes 0.000 claims 5
- 108010079505 Endostatins Proteins 0.000 claims 5
- AAFYOVPTFNNVDN-UHFFFAOYSA-N N-methyl-N-phenacylnitrous amide Chemical compound O=NN(C)CC(=O)C1=CC=CC=C1 AAFYOVPTFNNVDN-UHFFFAOYSA-N 0.000 claims 5
- 206010029113 Neovascularisation Diseases 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 150000001413 amino acids Chemical group 0.000 claims 4
- 230000003612 virological Effects 0.000 claims 4
- 229930002945 all-trans-retinaldehyde Natural products 0.000 claims 3
- 210000004027 cells Anatomy 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 230000002207 retinal Effects 0.000 claims 3
- 235000020945 retinal Nutrition 0.000 claims 3
- 239000011604 retinal Substances 0.000 claims 3
- 201000010874 syndrome Diseases 0.000 claims 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 2
- 208000008425 Protein Deficiency Diseases 0.000 claims 2
- WYTGDNHDOZPMIW-UHOFOFEASA-O Serpentine Natural products O=C(OC)C=1[C@@H]2[C@@H]([C@@H](C)OC=1)C[n+]1c(c3[nH]c4c(c3cc1)cccc4)C2 WYTGDNHDOZPMIW-UHOFOFEASA-O 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 239000000790 retinal pigment Substances 0.000 claims 2
- 241000432074 Adeno-associated virus Species 0.000 claims 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 claims 1
- 208000009361 Bacterial Endocarditis Diseases 0.000 claims 1
- 206010059449 Candida endophthalmitis Diseases 0.000 claims 1
- 210000003161 Choroid Anatomy 0.000 claims 1
- 208000002765 Choroid Disease Diseases 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010070957 Choroidal haemangioma Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 206010008790 Choroidal rupture Diseases 0.000 claims 1
- 208000002691 Choroiditis Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010014666 Endocarditis bacterial Diseases 0.000 claims 1
- 206010051045 Eye naevus Diseases 0.000 claims 1
- 208000001034 Frostbite Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000002927 Hamartoma Diseases 0.000 claims 1
- 208000005100 Herpetic Keratitis Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022114 Injury Diseases 0.000 claims 1
- 240000001549 Ipomoea eriocarpa Species 0.000 claims 1
- 235000005146 Ipomoea eriocarpa Nutrition 0.000 claims 1
- 210000000554 Iris Anatomy 0.000 claims 1
- 235000019766 L-Lysine Nutrition 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 206010025412 Macular dystrophy congenital Diseases 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 210000001577 Neostriatum Anatomy 0.000 claims 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 claims 1
- 210000003733 Optic Disk Anatomy 0.000 claims 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims 1
- 208000008798 Osteoma Diseases 0.000 claims 1
- 206010073286 Pathologic myopia Diseases 0.000 claims 1
- 210000002381 Plasma Anatomy 0.000 claims 1
- 206010064714 Radiation retinopathy Diseases 0.000 claims 1
- 208000004644 Retinal Vein Occlusion Diseases 0.000 claims 1
- 206010038848 Retinal detachment Diseases 0.000 claims 1
- 208000007014 Retinitis Pigmentosa Diseases 0.000 claims 1
- 206010038932 Retinopathy Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010038935 Retinopathy sickle cell Diseases 0.000 claims 1
- 229940005550 Sodium alginate Drugs 0.000 claims 1
- 241000519995 Stachys sylvatica Species 0.000 claims 1
- 241000223996 Toxoplasma Species 0.000 claims 1
- 206010064996 Ulcerative keratitis Diseases 0.000 claims 1
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 claims 1
- 206010047141 Vasodilatation Diseases 0.000 claims 1
- 210000003462 Veins Anatomy 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims 1
- 241001135917 Vitellaria paradoxa Species 0.000 claims 1
- 206010047680 Vogt-Koyanagi-Harada syndrome Diseases 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 239000000783 alginic acid Substances 0.000 claims 1
- 229960001126 alginic acid Drugs 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 150000004781 alginic acids Chemical class 0.000 claims 1
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 201000005667 central retinal vein occlusion Diseases 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 201000007717 corneal ulcer Diseases 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229960003646 lysine Drugs 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000003142 neovascular glaucoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000649 photocoagulation Effects 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
- 230000002028 premature Effects 0.000 claims 1
- 201000008171 proliferative glomerulonephritis Diseases 0.000 claims 1
- 230000004242 retinal defects Effects 0.000 claims 1
- 230000004264 retinal detachment Effects 0.000 claims 1
- 201000001949 retinal vasculitis Diseases 0.000 claims 1
- 201000005404 rubella Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000003248 secreting Effects 0.000 claims 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 claims 1
- 239000000661 sodium alginate Substances 0.000 claims 1
- 235000010413 sodium alginate Nutrition 0.000 claims 1
- 210000001519 tissues Anatomy 0.000 claims 1
- 230000001052 transient Effects 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- 230000024883 vasodilation Effects 0.000 claims 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 claims 1
- 208000006542 von Hippel-Lindau Disease Diseases 0.000 claims 1
Claims (27)
- 眼球血管新生に罹患した個体の眼組織中のエンドスタチンの量を眼球血管新生阻害有効量へ高めることができる、眼球血管新生処置用医薬。
- エンドスタチンが配列番号1に示すアミノ酸配列を有するポリペプチドである、請求項1の医薬。
- エンドスタチンが配列番号1に示すアミノ酸配列を有するポリペプチドのポリペプチドフラグメント、配列番号1に示すアミノ酸配列を有するポリペプチドの誘導体、または配列番号1に示すアミノ酸配列を有するポリペプチドの変異体である、請求項1の医薬。
- エンドスタチンが個体にとって外生(exogenous)である、請求項1〜3の何れかの医薬。
- エンドスタチンコード核酸を含むウイルスベクターを含有する、眼球血管新生処置用医薬。
- ウイルスベクターがアデノウイルス、アデノ随伴ウイルス、レトロウイルスおよびレンチウイルスからなる群より選択される、請求項5の医薬。
- ウイルスベクターがアデノウイルスベクターである、請求項6の医薬。
- エンドスタチンを分泌するセルを含む、個体内にインプラントするためのマイクロカプセル。
- マイクロカプセルがアルギン酸塩を含む、請求項8のマイクロカプセル。
- マイクロカプセルがアルギン酸ナトリウムを含む、請求項9のマイクロカプセル。
- マイクロカプセルがアルギン酸カルシウムを含む、請求項10のマイクロカプセル。
- マイクロカプセルがポリL−リジンを含む、請求項11のマイクロカプセル。
- セルが外生エンドスタチンコード核酸を含む、請求項8のマイクロカプセル。
- セルが外生エンドスタチンコード遺伝子を過剰発現する、請求項8のマイクロカプセル。
- ベクターが108プラーク形成単位ないし1014プラーク形成単位で存在する、請求項5の医薬。
- ベクターが108プラーク形成単位ないし1014プラーク形成単位で存在する、請求項7の医薬。
- エンドスタチンコード核酸が配列番号2に示す配列を有する、請求項5の医薬。
- 眼球血管新生がヒストプラズマ症、病的近視、網膜色素線条、前部虚血性視神経症、細菌性心内膜炎、Best病、birdshot網膜脈絡膜病、脈絡膜血管腫、脈絡膜母斑、脈絡膜非潅流、脈絡膜骨腫、脈絡膜破裂、先天性脈絡膜欠如、慢性網膜剥離、網膜の欠損、ドルーゼ、内因性カンジダ眼内炎、網膜色素上皮の過剰乳頭状過誤腫、黄色斑眼底、特発性、黄斑円孔、悪性黒色腫、膜増殖性糸球体腎炎(II型)、金属性眼内異物、朝顔円盤症候群、多発性一過性白点症候群(MEWDS)、鋸状炎の血管新生、手術顕微鏡熱傷、視神経頭小窩、光凝固術、斑点状内部脈絡膜症、風疹、類肉腫症、蛇行性または地図状脈絡膜症、網膜下排液、傾斜性椎間板症候群、トキソプラズマ網脈絡膜炎、結核、Vogt-Koyanagi-Harada症候群、糖尿病性網膜症、非糖尿病性網膜症、枝静脈閉塞、中枢網膜静脈閉塞、未成熟幼児の網膜症、虹彩ルベオシス、新生血管緑内障、perifoveal網膜血管拡張症、鎌状細胞網膜症、Eale病、網膜脈管炎、Von Hippel Lindau病、放射線網膜症、網膜凍傷、色素性網膜症、網脈絡膜欠損症、単純ヘルペス角膜炎、角膜潰瘍、角膜移植、pterigyiaおよび外傷からなる群より選択される因子によって引き起こされている、請求項1の医薬。
- 眼球血管新生が脈絡膜血管新生である、請求項18の医薬。
- 眼内投与のための、請求項5の医薬。
- 網膜下投与のための、請求項20の医薬。
- 硝子体内投与のための、請求項20の医薬。
- ウイルスベクターがレンチウイルスベクターである、請求項6の医薬。
- レンチウイルスベクターがウシ免疫不全ウイルスベクターである、請求項23の医薬。
- 眼内投与のための、請求項24の医薬。
- 網膜下投与のための、請求項25の医薬。
- 硝子体内投与のための、請求項26の医薬。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27078701P | 2001-02-22 | 2001-02-22 | |
US60/270,787 | 2001-02-22 | ||
US28129601P | 2001-04-04 | 2001-04-04 | |
US60/281,296 | 2001-04-04 | ||
PCT/US2002/005336 WO2002067971A2 (en) | 2001-02-22 | 2002-02-21 | Use of endostatin in the treatment of ocular neovascularization |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2004527494A JP2004527494A (ja) | 2004-09-09 |
JP2004527494A5 true JP2004527494A5 (ja) | 2006-01-05 |
JP4689144B2 JP4689144B2 (ja) | 2011-05-25 |
Family
ID=26954498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002567337A Expired - Lifetime JP4689144B2 (ja) | 2001-02-22 | 2002-02-21 | 眼球血管新生を処置するための方法 |
Country Status (5)
Country | Link |
---|---|
US (3) | US20020183253A1 (ja) |
EP (1) | EP1401480B1 (ja) |
JP (1) | JP4689144B2 (ja) |
AU (1) | AU2002240463A1 (ja) |
WO (1) | WO2002067971A2 (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040234505A1 (en) * | 1998-09-23 | 2004-11-25 | Stuart Naylor | Polynucleotide constructs and uses thereof |
US7122181B2 (en) * | 2000-12-19 | 2006-10-17 | Research Development Foundation | Lentiviral vector-mediated gene transfer and uses thereof |
EP1401480B1 (en) | 2001-02-22 | 2012-11-28 | Novartis AG | Viral vectors encoding endostatin in the treatment of ocular neovascularization |
US6875165B2 (en) | 2001-02-22 | 2005-04-05 | Retinalabs, Inc. | Method of radiation delivery to the eye |
WO2003066810A2 (en) * | 2002-02-04 | 2003-08-14 | Novartis Ag | Recombinant bovine immunodeficiency virus based gene transfer system |
CA2480809A1 (en) * | 2002-04-11 | 2003-10-23 | Children's Medical Center Corporation | Methods for inhibiting vascular hyperpermeability |
DE60332122D1 (de) * | 2002-08-28 | 2010-05-27 | Novartis Ag | Gentherapie des auges |
US20060251621A1 (en) * | 2002-09-27 | 2006-11-09 | Campochiaro Peter A | Ocular gene therapy |
GB0402100D0 (en) * | 2004-01-30 | 2004-03-03 | Novartis Ag | Organic compounds |
WO2005079915A1 (en) | 2004-02-12 | 2005-09-01 | Neo Vista, Inc. | Methods and apparatus for intraocular brachytherapy |
US7803103B2 (en) | 2005-02-11 | 2010-09-28 | Neovista Inc. | Methods and apparatus for intraocular brachytherapy |
DK1767545T3 (da) | 2005-09-22 | 2010-03-15 | Biocompatibles Uk Ltd | GLP-1 (Glucagon-lignende peptid-1)-fusionspolypeptider med forøget peptidaseresistens |
ATE444741T1 (de) | 2006-05-10 | 2009-10-15 | Biocompatibles Uk Ltd | Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung |
US8353812B2 (en) | 2008-06-04 | 2013-01-15 | Neovista, Inc. | Handheld radiation delivery system |
EP2251028A1 (en) * | 2009-05-12 | 2010-11-17 | Biocompatibles Uk Ltd. | Treatment of eye diseases using encapsulated cells encoding and secreting an anti-angiogenic factor and/or a neuroprotective factor |
CN104548067A (zh) * | 2014-12-23 | 2015-04-29 | 浙江省人民医院 | 重组人血管内皮抑制素在制备治疗眼表新生血管性疾病药物中的应用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545423A (en) * | 1991-11-25 | 1996-08-13 | Vivorx, Inc. | Cytoprotective, biocompatible, retrievable macrocapsule containment systems for biologically active materials |
WO1994012161A1 (en) * | 1992-11-24 | 1994-06-09 | Clover Consolidated, Limited | Cytoprotective, biocompatible, retrievable macrocapsules |
US5827702A (en) * | 1994-10-31 | 1998-10-27 | Genentech, Inc. | Ocular gene therapy |
US5854205A (en) * | 1995-10-23 | 1998-12-29 | The Children's Medical Center Corporation | Therapeutic antiangiogenic compositions and methods |
CN1202932A (zh) * | 1995-10-23 | 1998-12-23 | 儿童医学中心公司 | 治疗用抗血管生成的组合物和方法 |
US6174861B1 (en) * | 1996-10-22 | 2001-01-16 | The Children's Medical Center Corporation | Methods of inhibiting angiogenesis via increasing in vivo concentrations of endostatin protein |
WO1998049321A2 (en) * | 1997-04-28 | 1998-11-05 | Rhone-Poulenc Rorer S.A. | Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors |
WO1999015641A1 (en) * | 1997-09-24 | 1999-04-01 | The Regents Of The University Of California | Non-primate lentiviral vectors and packaging systems |
WO1999026480A1 (en) * | 1997-11-20 | 1999-06-03 | Genetix Pharmaceuticals, Inc. | Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases |
US6106826A (en) * | 1997-12-17 | 2000-08-22 | Wisconsin Alumni Research Foundation | Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy |
US6201104B1 (en) * | 1998-12-04 | 2001-03-13 | Entremed, Inc. | Angiogenesis—inhibiting protein binding peptides and proteins and methods of use |
IT1312077B1 (it) * | 1999-04-15 | 2002-04-04 | Univ Degli Studi Milano | Polipeptidi ad attivita' antiangiogenica. |
US6267954B1 (en) * | 1999-11-24 | 2001-07-31 | Universite De Paris V Rene-Descartes | Intraocular transplantation of encapsulated cells |
US7125542B2 (en) * | 2000-02-10 | 2006-10-24 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
AU2002224403A1 (en) * | 2000-10-13 | 2002-04-22 | Entremed, Inc | Endostatin and pitslre protein kinases as angiogenesis-inhibiting peptides and method of use |
RU2288742C2 (ru) | 2000-12-19 | 2006-12-10 | Рисерч Дивелопмент Фаундейшн | Перенос генов, опосредованный лентивирусным вектором, и их использование |
US7122181B2 (en) | 2000-12-19 | 2006-10-17 | Research Development Foundation | Lentiviral vector-mediated gene transfer and uses thereof |
EP1401480B1 (en) | 2001-02-22 | 2012-11-28 | Novartis AG | Viral vectors encoding endostatin in the treatment of ocular neovascularization |
-
2002
- 2002-02-21 EP EP02706374A patent/EP1401480B1/en not_active Expired - Lifetime
- 2002-02-21 WO PCT/US2002/005336 patent/WO2002067971A2/en active Application Filing
- 2002-02-21 US US10/080,797 patent/US20020183253A1/en not_active Abandoned
- 2002-02-21 JP JP2002567337A patent/JP4689144B2/ja not_active Expired - Lifetime
- 2002-02-21 AU AU2002240463A patent/AU2002240463A1/en not_active Abandoned
-
2010
- 2010-05-23 US US12/785,461 patent/US8338384B2/en not_active Expired - Lifetime
-
2012
- 2012-12-17 US US13/716,925 patent/US9238057B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2004527494A5 (ja) | ||
Reichel et al. | Immune responses limit adenovirally mediated gene expression in the adult mouse eye | |
US8338384B2 (en) | Method for treating ocular neovascularization | |
US7989426B2 (en) | Selective induction of apoptosis to treat ocular disease by expression of PEDF | |
US20070098692A1 (en) | Materials and methods for treating ocular-related disorders | |
EP1463531B1 (en) | Methods for inhibiting ocular processes | |
Klausner et al. | Corneal gene therapy | |
US20090011040A1 (en) | Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases | |
Hauswirth et al. | Ocular gene therapy: quo vadis? | |
Liu et al. | Gene therapy targeting glaucoma: where are we? | |
US11739130B2 (en) | Delivery of card protein as therapy for ocular inflammation | |
US20140005257A1 (en) | Methods of gene therapy for treating disorders of the ear by administering a vector encoding an atonal-associated factor | |
AU2003297607A1 (en) | Materials and methods for treating ocular-related disorders | |
AU780634C (en) | Gene Therapy for treating ocular-related disorders | |
US20080227692A1 (en) | Compositions and methods for treating ophthalmic disorders | |
JP2007528903A (ja) | 眼における血管漏出を処置するための物質 | |
US20070232541A1 (en) | Methods of regulating angiogenisis through stabilization of pedf | |
Liu et al. | Ocular drug delivery: molecules, cells, and genes | |
Ali et al. | Co-injection of adenovirus expressing CTLA4-Ig prolongs adenovirally mediated lacZ reporter gene expression in the mouse retina | |
US20030170209A1 (en) | Use of a vector comprising a nucleic acid coding for an anti-angiogenic factor for treating corneal neovascularization | |
US20080107714A1 (en) | Use of a vector comprising a nucleic acid encoding an anti-angiogenic factor for the treatment of corneal neovascularization | |
WO2013067133A1 (en) | Production of tsg-6 protein | |
CN117089560A (zh) | 融合核酸、腺相关病毒载体及其用途和药物制剂 | |
US20200179482A1 (en) | Composition for and method of facilitating corneal tissue repair | |
JP2023531289A (ja) | 眼病態の処置のためのdna構造 |